These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
126 related items for PubMed ID: 23511925
1. Ultrashort-acting insulin may improve on 18F-FDG PET/CT image quality in patients with uncontrolled diabetic mellitus. Song HS, Yoon JK, Lee SJ, Yoon SH, Jo KS, An YS. Nucl Med Commun; 2013 Jun; 34(6):527-32. PubMed ID: 23511925 [Abstract] [Full Text] [Related]
2. Influence of subcutaneous administration of rapid-acting insulin in the quality of (18)F-FDG PET/CT studies. Garcia JR, Sanchis A, Juan J, Tomas J, Domenech A, Soler M, Moragas M, Riera E. Nucl Med Commun; 2014 May; 35(5):459-65. PubMed ID: 24535382 [Abstract] [Full Text] [Related]
3. Do hyperglycemia and diabetes affect the incidence of false-negative 18F-FDG PET/CT studies in patients evaluated for infection or inflammation and cancer? A Comparative analysis. Rabkin Z, Israel O, Keidar Z. J Nucl Med; 2010 Jul; 51(7):1015-20. PubMed ID: 20554733 [Abstract] [Full Text] [Related]
4. Impact of blood glucose, diabetes, insulin, and obesity on standardized uptake values in tumors and healthy organs on 18F-FDG PET/CT. Büsing KA, Schönberg SO, Brade J, Wasser K. Nucl Med Biol; 2013 Feb; 40(2):206-13. PubMed ID: 23228852 [Abstract] [Full Text] [Related]
5. Proposal for an optimized protocol for intravenous administration of insulin in diabetic patients undergoing (18)F-FDG PET/CT. Caobelli F, Pizzocaro C, Paghera B, Guerra UP. Nucl Med Commun; 2013 Mar; 34(3):271-5. PubMed ID: 23250295 [Abstract] [Full Text] [Related]
6. Does hyperglycemia affect the diagnostic value of 18F-FDG PET/CT? Mirpour S, Meteesatien P, Khandani AH. Rev Esp Med Nucl Imagen Mol; 2012 Mar; 31(2):71-7. PubMed ID: 22088805 [Abstract] [Full Text] [Related]
7. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system. Schmidt H, Brendle C, Schraml C, Martirosian P, Bezrukov I, Hetzel J, Müller M, Sauter A, Claussen CD, Pfannenberg C, Schwenzer NF. Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008 [Abstract] [Full Text] [Related]
8. Utility of Short-Acting Intravenous Insulin Therapy in Preparation of F-18 Fluorodeoxyglucose Positron Emission Tomography Computed Tomography Scan in Cancer Patients Incidentally Detected with High Blood Glucose Levels on the Day of Test. Rallapeta RP, Manthri RG, Kalawat T, Sachan A, Lakshmi AY, Hulikal N. Indian J Nucl Med; 2020 May; 35(2):110-115. PubMed ID: 32351264 [Abstract] [Full Text] [Related]
9. Semiquantitative Analysis of the Biodistribution of the Combined ¹⁸F-NaF and ¹⁸F-FDG Administration for PET/CT Imaging. Minamimoto R, Mosci C, Jamali M, Barkhodari A, Habte F, Jackson T, Mittra E, Gambhir SS, Iagaru A. J Nucl Med; 2015 May; 56(5):688-94. PubMed ID: 25840978 [Abstract] [Full Text] [Related]
11. Spatial and temporal heterogeneity of regional myocardial uptake in patients without heart disease under fasting conditions on repeated whole-body 18F-FDG PET/CT. Inglese E, Leva L, Matheoud R, Sacchetti G, Secco C, Gandolfo P, Brambilla M, Sambuceti G. J Nucl Med; 2007 Oct; 48(10):1662-9. PubMed ID: 17873124 [Abstract] [Full Text] [Related]
12. 18F-FDG PET-CT scanning and diabetic patients: what to do? Martin J, Saleem N. Nucl Med Commun; 2014 Dec; 35(12):1197-203. PubMed ID: 25211626 [Abstract] [Full Text] [Related]
15. [The application of (18)F fluorodeoxyglucose-positron emission tomography/computed tomography in the diagnosis and treatment of dermatomyositis]. Pei L, Guan ZW, Ji XJ, Wen QF, Sun F, Zhao Z, Jin JY, Zhu J, Zhang JL, Huang F. Zhonghua Nei Ke Za Zhi; 2016 Jul 01; 55(7):525-30. PubMed ID: 27373287 [Abstract] [Full Text] [Related]
16. [Appropriate uptake period for myocardial PET imaging with 18F-FDG after oral glucose loading]. Brink I, Nitzsche EU, Mix M, Schindler T, Hentschel M, Högerle S, Moser E. Nuklearmedizin; 2003 Feb 01; 42(1):39-44. PubMed ID: 12601453 [Abstract] [Full Text] [Related]
17. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions. Eiber M, Takei T, Souvatzoglou M, Mayerhoefer ME, Fürst S, Gaertner FC, Loeffelbein DJ, Rummeny EJ, Ziegler SI, Schwaiger M, Beer AJ. J Nucl Med; 2014 Feb 01; 55(2):191-7. PubMed ID: 24309383 [Abstract] [Full Text] [Related]
18. PET/MR imaging in the detection and characterization of pulmonary lesions: technical and diagnostic evaluation in comparison to PET/CT. Rauscher I, Eiber M, Fürst S, Souvatzoglou M, Nekolla SG, Ziegler SI, Rummeny EJ, Schwaiger M, Beer AJ. J Nucl Med; 2014 May 01; 55(5):724-9. PubMed ID: 24652827 [Abstract] [Full Text] [Related]
19. Lower maximum standardized uptake value of fluorine-18 fluorodeoxyglucose positron emission tomography coupled with computed tomography imaging in pancreatic ductal adenocarcinoma patients with diabetes. Chung KH, Park JK, Lee SH, Hwang DW, Cho JY, Yoon YS, Han HS, Hwang JH. Am J Surg; 2015 Apr 01; 209(4):709-16. PubMed ID: 25616974 [Abstract] [Full Text] [Related]
20. 18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy. Huang WY, Kao CH, Huang WS, Chen CM, Chang LP, Lee MS, Chao HL, Chiu CH, Lo CH, Jen YM. J Nucl Med; 2013 Oct 01; 54(10):1710-6. PubMed ID: 23970365 [Abstract] [Full Text] [Related] Page: [Next] [New Search]